Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance.

Original Citation:
Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. / Palumbo A; Palladino C. - In: THERAPEUTIC ADVANCES IN DRUG SAFETY. - ISSN 2042-0986. - 3(2012), pp. 255-266.

Availability:
This version is available http://hdl.handle.net/2318/150511 since

Published version:
DOI:10.1177/2042098612452291

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
This is an author version of the contribution published on:

Palumbo A, Palladino C
Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2012) 3
DOI: 10.1177/2042098612452291

The definitive version is available at:
Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance

Antonio Palumbo and Carmela Palladino

Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, Torino, Italy;

Abstract

Oral immunomodulatory drugs (IMiDs), namely thalidomide, lenalidomide and pomalidomide, interfere with several pathways important for disease progression. Today they play a crucial role in the treatment of multiple myeloma patients, and have considerably improved myeloma outcomes. These agents, and thalidomide in particular, are associated with higher rates of thromboembolic events, both venous and arterial. Individual risk factors for thromboembolic events include advanced age, previous history of thromboembolism, an indwelling central venous catheter, comorbid conditions (e.g. infections, diabetes, cardiac disease, obesity), current or recent immobilization, recent surgery and inherited thrombophilic abnormalities. Cancer therapy and cancer itself also increase the risk of thromboembolic events. The aim of this review is to help clinicians to define the risk of thrombotic events in patients treated with thalidomide and thus to provide practical recommendations to manage thromboprophylaxis in these patients.

Keywords: thalidomide, multiple myeloma, venous thromboembolism, novel agents, aspirin, warfarin, heparin, thromboprophylaxis

Introduction

Thalidomide belongs to the category of immunomodulatory drugs (IMiDs) together with the second-generation lenalidomide and pomalidomide. IMiDs have been shown to block several pathways important for disease progression demonstrating anti-angiogenic, immunomodulatory and apoptotic effects [Anderson, 2005]. After being withdrawn from the world market because of its teratogenicity, thalidomide is today approved for the therapy of some inflammatory and autoimmune disorders, including certain late-stage AIDS symptoms, and plays a crucial role in the therapy of multiple myeloma.

Trials have reported numerous thromboembolic events attributed to thalidomide therapy, especially when thalidomide is used in combination with chemotherapy. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are more common, but occasional arterial thrombotic events have also been detected [Palumbo et al. 2008a; Scarpace et al. 2005].

Although the introduction of IMiDs and thalidomide in cancer therapy, and multiple myeloma in particular, has considerably improved outcome, they have also increased the risk of thromboembolic events. Accurate evaluation of thromboembolic risk and appropriate thromboprophylaxis are recommended to improve the safety profile of the thalidomide-based therapy and optimize patient outcome [Palumbo et al. 2008b].
Which antithrombotic agent is the most appropriate is still a matter of debate; aspirin (ASA), low-molecular weight heparin (LMWH) and warfarin all seem to be effective. This review discusses risk factors for thromboembolism in the general population and, in particular, in multiple myeloma patients receiving thalidomide, and proposes clinical practical recommendations for thromboprophylaxis in this setting.

**Brief history of thalidomide**

Thalidomide is a synthetic glutamic acid derivative that consists of a chiral center and two amide rings. It is poorly soluble in water, hence no parental preparation is available (Figure 1). This drug exhibits linear and dose-dependent pharmacokinetics that are not affected by age, sex, race, food or smoking status [Weber, 2003].

![Figure 1. Molecular structure of thalidomide and most common adverse events. DVT, deep vein thrombosis.](image)

Thalidomide and IMiDs inhibit the cytokines tumor necrosis factor-α (TNF-α), interleukins (IL) 1β, 6, 12, and granulocyte macrophage-colony stimulating factor (GM-CSF). TNF-α enhances neoangiogenesis, and interacts with other proliferative cytokines such as IL-6, known to be involved in the pathogenesis of multiple myeloma [Thomas and Kantarjian, 2001]. Thalidomide also inhibits IL-12 monocyte production, and enhances lymphocytes synthesis of IL-12 determining an enhancement in the cytotoxic activity mediated by natural killer (NK) cells. IL1 β along with TNF-α are implicated in tumorigenesis upregulating the expression of vascular cell adhesion molecules (VCAM) promoting cancer cell adhesion and metastasis [Vidal-Vanaclocha et al. 2000]. IMiDs induce an IL-2-mediated primary T-cell proliferation increasing NK cell numbers and function, thus increasing the activity of NK-dependent cytotoxicity. IMiDs cause a concomitant increase in interferon gamma (IFN-γ) production and decrease in the density of TNF-α-induced cell surface adhesion molecules ICAM-1, VCAM-1 and E-selectin, thus altering the interactions between myeloma cells and the bone marrow microenvironment. Finally, IMiDs activate apoptotic pathways through caspase-8-mediated cell death and, at the mitochondrial level, through the c-jun terminal kinase (JNK)-dependent release of cytochrome-c and Smac into the cytosol of cells [Anderson, 2005].

Some of the above immunomodulatory activities along with anti-angiogenic, antiproliferative and pro-apoptotic properties are thought to mediate the antitumor responses to IMiDs observed in relapsed and refractory multiple myeloma and some solid tumor cancers [Teo, 2005].

Thalidomide was launched by Grünenthal on 1 October 1957; at first it was used as tranquilizer and painkiller and was effective against insomnia, coughs, colds and headaches. It was also found to be
an effective antiemetic, with an inhibitory effect on morning sickness during pregnancy. In the early 1960s the drug was withdrawn from the world market due to the discovery of its teratogenic effect (phocomelia). It has then been selectively reintroduced for use in various disorders thought to have an autoimmune or inflammatory basis.

The drug has been used in a variety of dermatologic conditions during the past few decades, including erythema nodosum leprosum, prurigo nodularis, actinic prurigo, discoid lupus erythematosus, aphthous stomatitis, Behçet’s syndrome and graft-versus-host disease [Tseng et al. 1996]. Researchers continue to investigate thalidomide for use in treating a variety of diseases and conditions, and nowadays it has become one of the most widely used drugs to treat multiple myeloma. Moreover, thalidomide has shown promising results for the treatment of inflammatory diseases, HIV-related mouth and throat ulcers and Kaposi’s sarcoma, but further investigation is needed.

Thalidomide is a known teratogenic agent, and its use is absolutely contraindicated in pregnant women. Sedation, constipation and pruritus are its most frequently noted side effects. A sensorimotor peripheral neuropathy usually of hands and feet may occur, particularly after prolonged exposure. Less common effects include peripheral edema, tremors, bradycardia, hypothyroidism and hepatic enzyme elevation [Weber, 2003]. Venous thromboembolism (VTE) events are commonly associated with the use of thalidomide [Scarpace et al. 2005]. Deep vein thrombosis (DVT) is the predominant event, occurring in veins deep within the muscles of the leg and in the pelvis; DVT occurs when part or all of a thrombus breaks away from the blood vessel wall; this clot or embolus is sometime carried in the direction of blood flow, to the pulmonary vessels. For this reason patients with DVT are at risk of PE as well, a life-threatening event. PE is a potentially lethal complication of DVT, leading to sudden death in one fourth of all cases [Heit et al. 1999].

Arterial thromboembolism is a sudden interruption of blood flow to an organ or body part due to a clot (embolus); it is increasingly being recognized as a complication of cancer therapy, although the underlying mechanisms are poorly understood [Lacy, 2010].

Atrial fibrillation (AF) is the most common arrhythmia seen in clinical practice; without appropriate anticoagulant treatment, most patients with AF are at increased risk of cardioembolic stroke. Coronary artery disease (CAD) is the most common form of cardiovascular disease. In CAD, atherosclerosis damages the coronary artery wall, predisposing to thrombus formation. The symptoms and severity of acute coronary syndromes (unstable angina and myocardial infarction) vary depending on the degree to which thrombi occlude the coronary arteries [Fuster et al. 2005; Bassand et al. 2007; Rosamond et al. 2008; Lloyd-Jones et al. 2010].

**Thalidomide and multiple myeloma**

Thalidomide received the approval by the United States Food and Drug Administration (FDA) for use in combination with high-dose dexamethasone as treatment for newly diagnosed multiple myeloma in 2006. In 2008, the European Medicines Agency (EMEA) granted approval for thalidomide in the treatment of newly diagnosed multiple myeloma in combination with melphalan and prednisone.

Thalidomide has been shown to have therapeutic activity as a single agent in patients with relapsed and/or refractory multiple myeloma. Thalidomide monotherapy can induce remissions in about one third of relapsing or refractory patients [Dimopoulos et al. 2003; Barlogie et al. 2001; Yakoub-Agha et al. 2002; Neben et al. 2002; Kumar et al. 2003] and combinations of thalidomide with
dexamethasone and/or chemotherapy can further improve response rates in these patients [Dimopoulos et al. 2003; Kropff et al. 2003]. Studies have shown good efficacy of thalidomide treatment in untreated patients [Dimopoulos et al. 2003].

Thalidomide has a wide spectrum of biological effects, including some that have been hypothesized to promote thrombosis, such as transient reduction of soluble thrombomodulin levels during the first month of therapy [Corso et al. 2004] and restoration of endothelial cell PAR-1 expression after damage from cytotoxic agents such as doxorubicin [Kausal et al. 2004]. The latter finding may in part explain the markedly higher thromboembolic risk seen with thalidomide–anthracycline combination therapy compared with thalidomide monotherapy, since IMiDs do not appear to cause endothelial injury themselves [Streetly et al. 2005]. Previous studies showed that single-agent thalidomide is not associated with an increased risk of thrombosis [Barlogie et al. 2001]. In relapsed/refractory multiple myeloma the incidence of VTE is <2% [Barlogie et al. 2001] and in newly diagnosed multiple myeloma the incidence of VTE is 3.5%. Combining thalidomide with dexamethasone has been clearly shown to increase the incidence of VTE; previous studies in newly diagnosed and relapsed/refractory multiple myeloma reported an incidence of 8–26% [Osman et al. 2001; Corso et al. 2004]. A significant increase in the risk of VTE during treatment with thalidomide and anthracyclines has been reported, especially during the first months of therapy [Barlogie et al. 2006]. With regards to alkylating agents, a phase II trial involving 50 elderly patients receiving melphalan, thalidomide and dexamethasone as initial therapy the incidence of VTE was around 9% [Dimopoulos et al. 2006]. In a randomized control trial assessing response rates of elderly patients with newly diagnosed multiple myeloma to melphalan, prednisone and thalidomide (MPT) as compared with melphalan–prednisone (MP) therapy, the incidence of VTE was 17% in the MPT arm and 2% in the MP arm [Palumbo et al. 2006]. The highest incidence of VTE (58%) in myeloma therapy was reported in a phase II trial evaluating the use of doxorubicin, vincristine and dexamethasone with thalidomide both in newly diagnosed and in relapsed/refractory multiple myeloma patients [Baz et al. 2005].

**Risk factors for thromboembolism in the general population**

Thromboembolism is typical of older age, with an incidence of less than 2% in subjects younger than 55 years and more than 5% in patients older than 65 years [Silverstein et al. 1998].

The cause of thromboembolism is multifactorial and is often a consequence of a combination of risk factors. Thromboembolic risk factors can be categorized into individual and disease-related risk factors [Samama, 2000; Heit et al. 2000, 2002; Ageno et al. 2006; Bauer, 2001].

Individual risk factors include older age, comorbid conditions (such as obesity, infection, renal disease, pulmonary disease and arterial thromboembolism), heritable prothrombotic mutations, the presence of a central venous catheter (CVC) or pacemaker, previous history of thrombosis, pregnancy/preterium and use of drugs.

Inherited thrombophilic abnormalities may include antithrombin III deficiencies, protein C and S deficiencies, activated protein C resistance, factor V Leiden mutation, prothrombin gene mutation and high levels of homocysteine.

Disease-related factors include recent (generally less than 3 months) surgical procedures, including vertebroplasty and kyphoplasty, trauma or hospital admission, neurologic disease with subsequent high degree and prolonged immobilization, chronic clinical conditions (hyperviscosity, chronic renal disease, infections, cardiac disease and malignant neoplasm, such as myeloma, with or without chemotherapy), primary site of cancer (gastrointestinal, brain, lung, gynecologic, renal or
hematologic), initial 3–6 months after cancer diagnosis, antiangiogenic therapy (thalidomide, lenalidomide or bevacizumab) and erythropoiesis-stimulating agents

The simultaneous presence of more than one risk factor increases the risk of VTE (Table 1).

Table 1. Major risk factors for venous thromboembolism (VTE) and suggested actions.

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Individual</strong></td>
<td></td>
</tr>
<tr>
<td>• Previous central venous catheter or pacemaker</td>
<td>If no risk factor or only one is present</td>
</tr>
<tr>
<td>• History of VTE</td>
<td></td>
</tr>
<tr>
<td>• Hypercoagulable state thrombophilia</td>
<td></td>
</tr>
<tr>
<td>• Obesity (body mass index ≥ 30)</td>
<td></td>
</tr>
<tr>
<td>• Comorbidities: cardiac, diabetes, renal impairment, chronic inflammatory disease</td>
<td>If two or more risk factors are present</td>
</tr>
<tr>
<td>• High degree and prolonged immobilization</td>
<td></td>
</tr>
<tr>
<td>• Recent surgery (within about 40 days): neurotrauma, orthopedic, general, other</td>
<td>LMWH (high-risk prophylactic dose)</td>
</tr>
<tr>
<td>• Medications: erythropoietin, hormone replacement therapy, tamoxifen/ stilboestrol</td>
<td>Or</td>
</tr>
<tr>
<td>• New diagnosis of myeloma</td>
<td>WAR (target INR 2.5)</td>
</tr>
<tr>
<td>• Hyperviscosity</td>
<td></td>
</tr>
<tr>
<td><strong>Myeloma therapy</strong></td>
<td></td>
</tr>
<tr>
<td>• Doxorubicin</td>
<td>LMWH (high-risk prophylactic dose)</td>
</tr>
<tr>
<td>• High-dose steroid (≥480 mg/month dexamethasone or equivalent)</td>
<td>Or</td>
</tr>
<tr>
<td>• Combination chemotherapy</td>
<td>WAR (target INR 2.5)</td>
</tr>
<tr>
<td><strong>Bleeding</strong></td>
<td>Clinicians should consider whether the presence of bleeding risk is sufficient to preclude pharmacological thromboprophylaxis</td>
</tr>
<tr>
<td>• Active bleeding</td>
<td></td>
</tr>
<tr>
<td>• Hemophilia or other known bleeding disorder</td>
<td></td>
</tr>
<tr>
<td>• Platelet count &lt; 100 × 10^9/L</td>
<td></td>
</tr>
<tr>
<td>• Acute stroke in previous month [hemorrhagic or ischemic]</td>
<td></td>
</tr>
<tr>
<td>• Blood pressure &gt; 200 mmHg systolic or &gt; 120 mmHg diastolic</td>
<td></td>
</tr>
<tr>
<td>• Severe liver disease [abnormal PT or known varices]</td>
<td></td>
</tr>
<tr>
<td>• Severe renal disease [creatinine clearance &lt; 30 ml/min]</td>
<td></td>
</tr>
<tr>
<td>• Undergoing procedure or intervention with high bleeding risk</td>
<td></td>
</tr>
<tr>
<td>ASA, aspirin 81–325 mg once daily; LMWH, low molecular weight heparin, equivalent of enoxaparin 40 mg once daily; PT, prothrombin time; WAR, full-dose warfarin; INR, International Normalized Ratio.</td>
<td></td>
</tr>
</tbody>
</table>

Risk of thromboembolism in patients with cancer

The risk of thromboembolism is 7–10 times higher in patients with cancer compared with the normal population. The risk is considerably higher (28 times) in patients with hematologic cancer [Blom et al. 2005]. The pathophysiology of thrombosis in cancer is a complex process. The
interaction between malignant cells and monocyte/macrophage cells stimulates the release of TNF, IL-1 and IL-6, all causing endothelial damage. The interaction between tumor cells and macrophages also activates platelets, factor XII and X. Cysteine protease and tissue factor are highly expressed in cancer cells, have procoagulant activity and can directly activate factor X and VII [Bick, 2003; Prandoni et al. 2005]. The risk is usually higher in the first months after diagnosis. In cancer patients, the risk of thromboembolic events is increased with active therapy, immobilization, surgery and the presence of CVC. In cancer patients undergoing surgery, the risk of DVT is doubled after surgery, and the risk of PE is three times as high as compared with patients without cancer undergoing surgery [White et al. 2003].

Recently, the risk of VTE was also found to be increased by the administration of erythropoiesis-stimulating agents [FDA, 2010]. A previous trial reported an increased incidence of VTE in cancer patients treated with erythropoiesis-stimulating agents, doubled in patients using erythropoietin and treated with thalidomide compared with patients who were treated with thalidomide and not receiving erythropoietin [Anaisse et al. 2012]. To conclude, in cancer patients the risk of developing VTE is higher because of the presence of several risk factors, including cancer therapy itself.

**Thromboembolism in multiple myeloma patients treated with thalidomide**

Hypercoagulable states have been described in plasma cell dyscrasias without being specifically related to myeloma. The incidence of thromboembolic events in multiple myeloma varies from 3% to 10% [Srkalovic et al. 2004; Rajkumar et al. 2006]. Several mechanisms are implicated, yet the exact mechanisms associated with VTE in multiple myeloma are unclear. M-protein interacts with platelets, enhancing platelet adhesion and aggregation [Eby and Blinder, 2003]. Procoagulant antibody formation, paraprotein interference with fibrin structure, activated protein C resistance and endothelial damage may be considered important factors favoring thromboembolism in patients with multiple myeloma [Zangari et al. 2003]. The interaction between tumor cells and their microenvironment may explain the increased expression of von Willebrand and factor VIII. This close relationship may be responsible for increased secretion of proinflammatory cytokines such as IL-6 and TNF that can activate coagulation pathways [Fox and Kahn, 2005]. Thalidomide can enhance expression of tissue factor and vascular endothelial growth factor, downregulate thrombospondin and cause cytokine-mediated, activated protein C resistance. Thalidomide has been shown to increase the levels of von Willebrand factor and factor VIII. In addition thalidomide regulates the level of the prothrombotic factor COX-2 [Kristinsson, 2010].

In multiple myeloma, published studies showed that thalidomide alone as induction therapy or as maintenance approach after chemotherapy is associated with a low incidence of thromboembolism, below 5% [Rajkumar et al. 2003; Weber et al. 2003; Barlogie et al. 2001; Zonder, 2006] and that the major risk is in the first months after diagnosis. Thalidomide associated with dexamethasone was found to lead to increased thromboembolic risk. In a randomized trial by the Eastern Cooperative Oncology Group including 102 newly diagnosed patients with myeloma, the rate of thromboembolic events was 17% in subjects receiving thalidomide plus dexamethasone and 3% in those receiving dexamethasone alone [Rajkumar et al. 2006].

The VTE risk may decrease in relapsed/refractory patients because they are more likely to be treated with lower doses of thalidomide [Zangari et al. 2007; Niesvizky and Badros, 2010].

There appears to be a striking increase in the risk of developing thromboembolic events during treatment with thalidomide–anthracycline combination regimens, particularly during the first months of therapy [Barlogie et al. 2006]. The risk of developing thromboembolism during therapy with thalidomide-alkylating agent combination therapy may be increased as well, but not to the
same degree as with anthracyclines. The main chemotherapeutic regimens including thalidomide and the incidence of thromboembolic events are summarized in Table 2.

Table 2. Incidences of thromboembolism with regimens including thalidomide plus alkylating agents.

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Prophylaxis</th>
<th>Incidence</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>THAL 300 mg days 1–4, 17–20</td>
<td>None</td>
<td>10%</td>
<td>Dimopoulos et al. [2004]</td>
</tr>
<tr>
<td>DEX 12 mg/m² days 1–4, 17–20</td>
<td>None</td>
<td>10%</td>
<td>Dimopoulos et al. [2004]</td>
</tr>
<tr>
<td>MEL 8 mg/m² days 1–4</td>
<td>None*</td>
<td>20%*</td>
<td>Palumbo et al. [2006]</td>
</tr>
<tr>
<td>MEL 4 mg/m² days 1–7</td>
<td>None*</td>
<td>20%*</td>
<td>Palumbo et al. [2006]</td>
</tr>
<tr>
<td>PRED 40 mg/m² days 1–7</td>
<td>None</td>
<td>12%</td>
<td>Facon et al. [2007]</td>
</tr>
<tr>
<td>THAL 100 mg/day until progression</td>
<td>None</td>
<td>12%</td>
<td>Facon et al. [2007]</td>
</tr>
<tr>
<td>MEL 0.25 mg/kg days 1–4</td>
<td>None</td>
<td>12%</td>
<td>Facon et al. [2007]</td>
</tr>
<tr>
<td>PRED 2 mg/kg days 1–4</td>
<td>None</td>
<td>12%</td>
<td>Facon et al. [2007]</td>
</tr>
<tr>
<td>THAL 100–400 mg/day until end of MP</td>
<td>None</td>
<td>12%</td>
<td>Facon et al. [2007]</td>
</tr>
<tr>
<td>MEL 0.2 mg/kg days 1–4</td>
<td>None</td>
<td>6%</td>
<td>Hulin et al. [2009]</td>
</tr>
<tr>
<td>PRED 2 mg/kg days 1–4</td>
<td>None</td>
<td>6%</td>
<td>Hulin et al. [2009]</td>
</tr>
<tr>
<td>THAL 100 mg/day*</td>
<td>None</td>
<td>6%</td>
<td>Hulin et al. [2009]</td>
</tr>
<tr>
<td>MEL: 0.25 mg/kg days 1–4</td>
<td>40%</td>
<td>8%</td>
<td>Waage et al. [2010]</td>
</tr>
<tr>
<td>PRED: 100 mg/day days 1–4 for 6-week cycles until plateau</td>
<td>40%</td>
<td>8%</td>
<td>Waage et al. [2010]</td>
</tr>
<tr>
<td>THAL: 400 mg/day until plateau, reduced to 200 mg/day until progression</td>
<td>40%</td>
<td>8%</td>
<td>Waage et al. [2010]</td>
</tr>
<tr>
<td>MEL: 0.25 mg/kg</td>
<td>NR</td>
<td>10%</td>
<td>Wijermans et al. [2010]</td>
</tr>
<tr>
<td>PRED: 1 mg/kg days 1–5</td>
<td>NR</td>
<td>10%</td>
<td>Wijermans et al. [2010]</td>
</tr>
<tr>
<td>THAL: 200 mg/day for eight 4-week cycles, followed by 50 mg/day until relapse</td>
<td>NR</td>
<td>10%</td>
<td>Wijermans et al. [2010]</td>
</tr>
<tr>
<td>MEL: 9 mg/m² days 1–4</td>
<td>Yes</td>
<td>22.4%</td>
<td>Beksac et al. [2011]</td>
</tr>
<tr>
<td>PRED: 60 mg/m² days 1–4</td>
<td>Yes</td>
<td>22.4%</td>
<td>Beksac et al. [2011]</td>
</tr>
<tr>
<td>THAL: 100 mg/day for eight 6-week cycles, followed by 100 mg/day until relapse</td>
<td>Yes</td>
<td>22.4%</td>
<td>Beksac et al. [2011]</td>
</tr>
<tr>
<td>BOR: 1.3 mg/m² days 1, 4, 6, 8, 10, 22, 25, 29 and 32 during cycles 1–4; days 1, 8, 15 and 22 during cycles 5–9</td>
<td>Yes</td>
<td>5%</td>
<td>Palumbo et al. [2010]</td>
</tr>
<tr>
<td>MEL: 9 mg/m² days 1–4</td>
<td>Yes</td>
<td>5%</td>
<td>Palumbo et al. [2010]</td>
</tr>
<tr>
<td>PRED: 60 mg/m² days 1–4</td>
<td>Yes</td>
<td>5%</td>
<td>Palumbo et al. [2010]</td>
</tr>
<tr>
<td>THAL: 50 mg daily for nine 6-week cycles</td>
<td>Yes</td>
<td>5%</td>
<td>Palumbo et al. [2010]</td>
</tr>
<tr>
<td>CTX 500 mg orally days 1, 8, 15</td>
<td>None</td>
<td>3.2%</td>
<td>Sidra et al. [2006]</td>
</tr>
<tr>
<td>DEX 40 mg days 1–4, 15–18</td>
<td>None</td>
<td>3.2%</td>
<td>Sidra et al. [2006]</td>
</tr>
<tr>
<td>THAL 100–200 mg/day</td>
<td>None</td>
<td>3.2%</td>
<td>Sidra et al. [2006]</td>
</tr>
<tr>
<td>CTX 300 mg/m² each week</td>
<td>Warfarin</td>
<td>11.5%</td>
<td>Kyriakou et al. [2005]</td>
</tr>
<tr>
<td>DEX 40 mg/day for 4 days each month 1 mg/day</td>
<td>Warfarin</td>
<td>11.5%</td>
<td>Kyriakou et al. [2005]</td>
</tr>
<tr>
<td>THAL ≤300 mg/day</td>
<td>Warfarin</td>
<td>11.5%</td>
<td>Kyriakou et al. [2005]</td>
</tr>
<tr>
<td>CTX 50 mg/day</td>
<td>None</td>
<td>7%</td>
<td>Garcia-Sanz et al. [2004]</td>
</tr>
<tr>
<td>DEX 40 mg/day for 4 days every 3 weeks</td>
<td>None</td>
<td>7%</td>
<td>Garcia-Sanz et al. [2004]</td>
</tr>
<tr>
<td>THAL 200–800 mg/day</td>
<td>None</td>
<td>7%</td>
<td>Garcia-Sanz et al. [2004]</td>
</tr>
<tr>
<td>THAL 400 mg/day days 1–5, 14–18</td>
<td>None</td>
<td>4%</td>
<td>Dimopoulos et al. [2004]</td>
</tr>
<tr>
<td>DEX 20 mg/m² days 1–4, 15–18</td>
<td>None</td>
<td>4%</td>
<td>Dimopoulos et al. [2004]</td>
</tr>
<tr>
<td>CTX 150 mg/m² orally every 12 hours, days 1–5</td>
<td>None</td>
<td>4%</td>
<td>Dimopoulos et al. [2004]</td>
</tr>
<tr>
<td>THAL 100–400 mg/day</td>
<td>None</td>
<td>3%</td>
<td>Hovenga et al. [2005]</td>
</tr>
<tr>
<td>CTX 100–150 mg/day</td>
<td>None</td>
<td>3%</td>
<td>Hovenga et al. [2005]</td>
</tr>
<tr>
<td>DEX 20 mg/m² days 1–4, 9–12, 17–20</td>
<td>None</td>
<td>9%</td>
<td>Kropff et al. [2003]</td>
</tr>
<tr>
<td>THAL 100–400 mg/day</td>
<td>None</td>
<td>9%</td>
<td>Kropff et al. [2003]</td>
</tr>
<tr>
<td>CTX 300 mg/m² every 12 hours, days 1–3</td>
<td>None</td>
<td>9%</td>
<td>Kropff et al. [2003]</td>
</tr>
</tbody>
</table>

*After addition of enoxaparin 40 mg daily, incidence decreased to 3%, resulting in overall incidence of 12% for patients receiving MP + thalidomide on this study.

*44 dose reduction to 50 mg per day of thalidomide or placebo was allowed at the investigator’s discretion in the event of patient intolerance to the 100 mg/day dose, especially in case of mild or moderate peripheral neuropathy (grade 1 or 2).

BOR, bortezomib; CTX, cyclophosphamide; DEX, dexamethasone; MEL, melphalan; MP, melphalan + prednisone; NR, not reported; PRED, prednisone; THAL, thalidomide.
In conclusion, myeloma therapy-related risk factors include use of doxorubicin, high-dose steroids and combination chemotherapy [Bauer, 2001; Snowden et al. 2011].

**Thromboprophylaxis approaches available**

Several classes of agents have been used for prophylaxis of VTE. Most commonly used pharmacologic agents for thromboprophylaxis of VTE include: ASA, unfractionated heparin (UH; standard, low-dose or adjusted-dose), oral anticoagulants such as warfarin and LMWH.

To date, only one randomized study is currently available. This study compared the use of ASA and fixed low-dose warfarin versus LMWH to prevent thromboembolism in myeloma patients receiving thalidomide [Palumbo et al. 2011]: 667 patients with previously untreated myeloma who received thalidomide-containing regimens (with or without bortezomib), were randomly assigned to receive ASA (100 mg/day), warfarin (1.25 mg/day) or LMWH (enoxaparin 40 mg/day). There were 6.5% who had serious thromboembolic events, acute cardiovascular events or sudden death during the first 6 months (6.4% in the ASA group, 8.2% in the warfarin group and 5.0% in the LMWH group). Compared with LMWH, the absolute differences were 1.3% in the ASA group and 3.2% in the warfarin group. The risk of thromboembolism was 1.38 times higher in patients treated with thalidomide without bortezomib, suggesting a protective role of bortezomib against VTE. ASA and warfarin showed similar efficacy compared with LMWH, except in elderly patients, where warfarin was shown to be less effective than LMWH.

**LMWH**

The recommended dosage of LMWH in thalidomide treated patients is within the prophylactic range [Zangari et al. 2004]. The use of LMWH is more appropriate for cytopenic (mainly thrombocytopenic) patients. Nevertheless, this type of prophylaxis may increase the hemorrhagic risk and patients should be carefully monitored. Additional limiting aspects are the high cost of treatment, the lower patient compliance because of the need for self-injection and also the risk of renal impairment [Palumbo et al. 2011]. Indeed, most of LMWH is cleared via the renal route and LMWH therapy should be adjusted when the creatinine clearance is <30 ml/min to avoid drug accumulation and consequently an increase risk of bleeding. Kidney function is often altered in patients with multiple myeloma, thus a constant close monitoring is necessary when administering LMWH to these patients [Dimopoulos et al. 2008].

**Aspirin**

ASA showed to reduce the risk of arterial complication [Cohen et al. 1994] but its role in venous thromboprophylaxis remains controversial. Although LMWH and warfarin-type prophylaxes are considered more efficient, there are data demonstrating that ASA reduces the risk of VTE in multiple myeloma patients treated with thalidomide [Hovens et al. 2006; Niesvizky et al. 2007]. One trial has reported a protective role of ASA in first-line therapy of patients with multiple myeloma treated with thalidomide and anthracyclines. The rate of thrombosis dramatically decreased (from 55% to 18%) when ASA was administered [Baz et al. 2005]. A significant risk reduction in both arterial and venous thrombosis with ASA was seen also in other similar studies [Pulmonary Embolism Prevention (PEP) Trial Collaborative Group, 2000].
Warfarin

Warfarin is an oral anticoagulant commonly prescribed to treat VTE and to decrease the risk of VTE in AF [Ansell et al. 2008]. Warfarin therapy is complicated by the wide interindividual variation in response and dose requirements for adequate anticoagulation. Optimal warfarin therapy is achieved by maintaining the anticoagulation response, International Normalized Ratio (INR), within a narrow therapeutic range of 2.0–3.0 for most indications. In multiple myeloma, warfarin-type drugs increase the incidence of hemorrhage when the INR is above 3. This bleeding risk is further increased in patients who become thrombocytopenic particularly with a platelet count below 80 g/l. Owing to the unpredictable pharmacokinetic and pharmacodynamic responses to warfarin, initiation of therapy is the most clinically challenging phase as the optimal dose is often determined iteratively, guided by INR [Landefeld and Beyth, 1993]. Low-dose warfarin corresponds to a dose of 2.5–5 mg/day, while full dose warfarin corresponds to the dose adjusted according to INR (target 2.0–3.0). Fixed low-dose warfarin corresponds to warfarin 1–1.25 mg/day.

How to manage thromboembolic prophylaxis in patients receiving thalidomide-containing regimens

Patients receiving thalidomide with chemotherapy or dexamethasone are at high risk for thrombosis and warrant prophylaxis [Lyman et al. 2007, 2007]. The choice of thromboprophylaxis should be based on the presence of individual and myeloma-related risk factors. Patients may be divided into two subcategories: standard and high-risk patients. If none of these risk factors is present, the patient is considered at standard risk. The simultaneous presence of more than one risk factor exponentially increases the risk of VTE [Palumbo et al. 2008b]. Myeloma-related risk factors such as the combination of thalidomide with high-dose dexamethasone or doxorubicin or multi-agent chemotherapy should be considered as high-risk factors (Table 1).

In newly diagnosed myeloma patients treated with single-agent thalidomide, thromboprophylaxis is not usually recommended, while it is suggested when thalidomide is combined with other agents. The risk of VTE is much lower at relapse, so antithrombotic prophylaxis may be suggested only in high-risk patients in this setting. LMWH or full-dose warfarin should be administered in all patients who receive thalidomide with high-dose dexamethasone or doxorubicin or multi-agent chemotherapy.

LMWH prophylaxis is widely used, while warfarin is scarcely used in the routine clinical practice because of the risk of hemorrhage in patients receiving active chemotherapy that could increase the risk of thrombocytopenia. The correct dose of LMWH to administer for thromboprophylaxis is defined according to the patients’ weight; monitoring of the anti-Xa level is not required except in the case of extremes of body weight (<50 kg, >100 kg), prosthetic heart valves or impaired renal function.

A prophylactic anti-Xa level for LMWH is considered 0.1–0.3 IU/ml 4 hours after a dose of LMWH, in the case of prosthetic heart valves it is higher 0.8–1.2 IU/ml.

In case of thromboprophylaxis using dalteparin, the dose to administer is 2500–5000 units daily, while enoxaparin is 40 mg once daily.

Renal impairment may be a limit in the use of LMWH prophylaxis, due to the renal elimination of the drug, the consequent risk of accumulation and increased risk of bleeding. In this case, full-dose warfarin is recommended.
In patients presenting with a standard risk to develop VTE or treated with thalidomide as single-agent, anti-aggregation therapy with low-dose ASA should be considered. In the case of the presence of additional risk factors, which increase the risk of VTE, even in patients receiving thalidomide as a single agent, LWMH or full-dose warfarin are recommended (Table 1). Thromboprophylaxis should be continued for 3–6 months. Treatment with LMWH should be given for at least 6 months. Indefinite treatment should be considered for selected patients with active cancer, such as those with active disease and receiving chemotherapy. Anticoagulation should be avoided in the presence of intracranial bleeding, recent surgery, preexisting bleeding diathesis such as thrombocytopenia, platelet count <50,000/µl or coagulopathy.

For myeloma patients, constant monitoring of platelet count during chemotherapy and antithrombotic prophylaxis is necessary.

Rivaroxaban and dabigatran etexilate are the first new oral anticoagulants recently approved in the European Union, Canada and many other countries worldwide for the prevention of VTE in adult patients undergoing elective hip or knee replacement surgery [Friedman, 2009]. Fondaparinux is the first agent of a new class of selective factor Xa inhibitors (pentasaccharides). This drug was first approved for VTE prophylaxis in patients undergoing major orthopedic procedures and more recently was also approved to manage PE and DVT [Buller et al. 2003, 2004].

These newer and effective antithrombotic agents with reduced drug interactions and without the need for constant monitoring could optimize patient care and eventually modify the indication for use and duration of thromboprophylaxis, but further investigation is needed.

**Conclusion**

In conclusion, myeloma patients treated with thalidomide require routine thromboprophylaxis. ASA, LMWH and warfarin showed similar efficacy in reducing serious thromboembolic events, except in elderly patients where fixed low-dose warfarin showed less efficacy than LMWH. Although it could be an attractive option, fixed low-dose warfarin needs more extensive investigation.

The specific thromboprophylaxis should be given according to individual risk factors and the type of therapy. It is crucial to identify patients at high risk of VTE in order to intervene promptly and to administer an appropriate prophylaxis, thus limiting the incidence of serious adverse events.

**Acknowledgments**

The authors thank the editorial assistant, Giorgio Schirripa.

**Funding:** This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Conflict of interest statement:** Antonio Palumbo has received honoraria from Celgene, Janssen-Cilag, Merck, Amgen and served on the advisory committee of Celgene, Janssen-Cilag. Carmela Palladino has no conflicts of interest.
Contributor Information

Antonio Palumbo, Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, Torino, Italy.

Carmela Palladino, Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, Torino, Italy.

References